Abbott opens US$200 million electrophysiology plant in Querétaro

Abbott has inaugurated its new electrophysiology manufacturing plant in Querétaro, a strategic project that strengthens the state’s position as a hub for advanced medical device manufacturing and reinforces Mexico’s role in global healthcare value chains. The facility represents a US$200 million investment and will focus on producing specialized technologies for the diagnosis and treatment of cardiac rhythm disorders.

During the opening ceremony, Abbott executives emphasized that the plant is part of the company’s global growth strategy and its long-term commitment to Mexico. The new industrial complex will manufacture cardiac electrophysiology devices, a highly specialized segment within cardiology that directly supports the treatment of conditions such as atrial fibrillation.

In his remarks, Robert B. Ford, Chairman and CEO of Abbott, highlighted that the company selected Mexico and Querétaro due to the region’s skilled workforce, industrial capabilities, and competitive business environment. He noted that Abbott operates in more than 160 countries and manages over 90 manufacturing plants worldwide, making its expansion in Mexico a decision based on proven performance and long-term vision.

The facility will begin operations with the production of mapping and imaging catheters, devices that allow physicians to precisely identify electrical signals in the heart. In a later phase, Abbott plans to expand production to include ablation catheters, used in minimally invasive procedures to treat arrhythmias. This progression will further increase the site’s technological complexity and integration into the global medical device supply chain.

State authorities in Querétaro noted that the investment will drive the creation of highly specialized jobs, with the workforce projected to grow from approximately 300 employees today to more than 1,200 positions by the end of the decade. These roles are expected to focus on precision manufacturing, quality systems, and international regulatory compliance.

From an economic perspective, Abbott’s presence in this segment diversifies Querétaro’s industrial profile—traditionally strong in automotive and aerospace manufacturing—and opens new opportunities for the development of local suppliers linked to the medical device industry, one of the fastest-growing global markets.

With this new facility, Querétaro positions itself as a reference point for healthcare technology manufacturing, while Abbott strengthens its footprint in Mexico and expands its capacity to serve rising global demand for advanced medical devices, consolidating a long-term relationship between the company, the state, and the country.

Abbott is a global healthcare company with more than 130 years of experience, specializing in the development and manufacturing of medical technologies, diagnostics, nutrition products, and branded pharmaceuticals.

Operating in more than 160 countries with a network of over Abbott opens US$200 million electrophysiology plant in Querétaro, strengthening Mexico’s medical device manufacturing90 manufacturing sites worldwide, Abbott is recognized as a key innovator in areas such as cardiology, implantable devices, and chronic disease management, with a strong focus on quality, regulatory compliance, and specialized talent development.